February 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Kazia Therapeutics Limited
Acceleration Request for Registration Statement on Form F-1
File No. 333-276774
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kazia Therapeutics Limited (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 5, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927.
| Sincerely, |
| KAZIA THERAPEUTICS LIMITED |
/s/ John Friend |
| John Friend |
| Chief Executive Officer and Managing Director |
cc: John Friend, Chief Executive Officer and Managing Director, Kazia Therapeutics Limited
Stephanie Richards., Esq., Goodwin Procter LLP
